Year-end Sale % OFF 
Abstract
Daily administration of potent mouse interferon preparations, begun after clinical diagnosis of lymphoma in AKR mice, increased average survival by approximately 100%. Interferon treatment delayed the evolution of the lymphoma but regression of tumour was not observed. The therapeutic effects observed with interferon in AKR mice compare favorably with reported results obtained using standard anti-cancer drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
